AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

3.530

+0.010 (0.28%)

At close: Mar 19, 2026, 4:00 PM EDT

3.530

0.00 (0.00%)

Pre-market: Mar 20, 2026, 6:04 AM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Discovery and Development of Antibodies	75.13M	28.83M	38.03M	485.42M	375.20M
Discovery and Development of Antibodies Growth	160.56%	-24.17%	-92.17%	29.38%	60.92%
Total	75.13M	28.83M	38.03M	485.42M	375.20M
Total Growth	160.56%	-24.17%	-92.17%	29.38%	60.92%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Canada	75.13M	28.83M	38.03M	485.42M	375.20M
Canada Growth	160.56%	-24.17%	-92.17%	29.38%	60.92%
Total	75.13M	28.83M	38.03M	485.42M	375.20M
Total Growth	160.56%	-24.17%	-92.17%	29.38%	60.92%

Source: S&P Global Market Intelligence.